Therapy of infections caused by dematiaceous fungi.
Dematiaceous fungi are responsible for a wide variety of clinical syndromes, from local infections due to trauma, to disseminated infection in immunocompromised patients. These fungi are unique owing to the presence of melanin in their cell walls, which imparts the characteristic dark color to their spores and hyphae. Melanin may also be a virulence factor in these fungi. Therapy depends upon the clinical syndrome. Local infection may be cured with excision alone, while systemic disease is often refractory to therapy. Azoles such as itraconazole and voriconazole have the most consistent in vitro activity, although newer agents may also play a role in therapy in the future.
Revankar
Sanjay G
SG
Dallas VA Medical Center, 4500 S. Lancaster Road, Dallas, TX 75216, USA. sanjay.revankar@med.va.gov
D000935:Antifungal Agents / Q000627:therapeutic use*; D001922:Brain Abscess / Q000188:drug therapy / Q000382:microbiology; D004359:Drug Therapy, Combination; D005658:Fungi; D006801:Humans; D008172:Lung Diseases, Fungal / Q000188:drug therapy / Q000382:microbiology; D009181:Mycoses / Q000188:drug therapy* / Q000382:microbiology*; D012852:Sinusitis / Q000188:drug therapy / Q000382:microbiology
D000935:Antifungal Agents